Clinical trials
Advanced clinical trials
Below are recruiting advanced clinical trials, each written for real people, not researchers. We’re tracking 3,986 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06878625RecruitingPhase 2
Trop-2 drug combo for advanced triple-negative breast cancer
This trial tests a new drug combination (Trop-2 antibody-drug conjugate plus other therapies) for advanced triple-negative breast cancer that has spread or come back. It may offer a new option for people who have had only 1–2 prior chemotherapies and have not used immunotherapy or anti-angiogenic drugs before.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT06878664RecruitingPhase 3
Lu177-Dotatate vs standard care for slow-growing midgut neuroendocrine tumors
This trial tests whether a radioactive drug called Lu177-Dotatate (PRRT) works better than usual care for people with slow-growing, advanced midgut neuroendocrine tumors (NETs). It may help shrink or slow the growth of tumors when you also get somatostatin analog therapy.
Caen, CaenAges 18 years+ - NCT06881043Recruiting
Robotic surgery tool for advanced stomach cancer
This trial tests a robotic surgical tool that seals blood vessels in advanced stomach cancer. It aims to see if the tool works safely and effectively during robot-assisted surgery.
Changchun, JilinAges 18–75 - NCT06889766RecruitingPhase 1
NY-ESO-1 T cells for advanced melanoma and sarcoma
This trial tests a personalized cell therapy using your own immune cells (T cells) that have been modified to recognize a protein called NY-ESO-1, which is found on some melanoma and sarcoma tumors. It may help people whose cancer has progressed after standard treatments.
Lausanne, Canton of VaudAges 18 years+ - NCT06889883Recruiting
Blood test for early colorectal cancer detection
This study is testing a new blood test to find colorectal cancer early. You may be able to join if you are about to have a colonoscopy or surgery for a suspected tumor.
Zaragoza, AragonAges 18 years+ - NCT06890637Recruiting
Fecal transplant and diet change for Crohn's disease
This trial tests whether a fecal transplant (putting healthy bacteria into your gut) combined with dietary changes can help control active Crohn's disease. It is for people who need stronger treatments or have stopped responding to their current therapy.
Kochi, KeralaAges 18–75 - NCT06893380Recruiting
Drug combo plus immunotherapy for advanced bile duct cancer
This study tests a combination of three drugs (gemcitabine, cisplatin, nab-paclitaxel) plus an immunotherapy (tislelizumab) for people with advanced biliary tract cancer who haven't had treatment yet. The goal is to see if this cocktail shrinks tumors better than standard care.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT06895291Recruiting
Whole body MRI for cancer patients
This study uses whole-body MRI scans to see if they help monitor or diagnose cancer better. It may be an option if your doctor has already recommended this type of scan.
Bologna, BOAges 18 years+ - NCT06897644RecruitingPhase 3
Comparing two chemotherapy strategies for advanced pancreatic cancer
This study compares two chemotherapy strategies for people with advanced pancreatic cancer who have not yet had treatment. The goal is to see if switching to a different chemotherapy combination (gemcitabine plus nab-paclitaxel) after initial treatment works better than staying on the original chemotherapy (modified FOLFIRINOX).
Aviano, ItalyAges 18 years+ - NCT06898450RecruitingPhase 1/Phase 2
Study of new drug NDI-219216 for advanced solid tumors
This study tests a new drug called NDI-219216 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and can help shrink or control the cancer.
Los Angeles, CaliforniaAges 18–99 - NCT06906445Recruiting
Fecal transplant and diet changes for ulcerative colitis
This trial tests if a fecal transplant combined with dietary changes can help control symptoms in people with active ulcerative colitis who haven't responded well to standard treatments or advanced therapies.
Kochi, KeralaAges 18–75 - NCT06906562RecruitingPhase 2
Pemigatinib for advanced pancreatic cancer with FGFR changes
This trial tests a targeted pill, pemigatinib, for people with advanced pancreatic cancer that has a specific FGFR gene change. The study is done entirely through telemedicine, so you can participate from home if eligible.
Birmingham, AlabamaAges 18 years+ - NCT06907043RecruitingPhase 1/Phase 2
Study of PARP1 inhibitor EIK1004 for advanced solid tumors
This trial is testing a new drug (EIK1004) designed to block a protein called PARP1, which helps repair DNA. It is for people with advanced solid tumors, especially those with BRCA or other DNA repair gene mutations. The goal is to see if it can shrink tumors or slow their growth.
Denver, ColoradoAges 18–89 - NCT06907602RecruitingPhase 2/Phase 3
Optimizing treatment before surgery for advanced esophageal cancer
This trial tests different combinations of treatments given before surgery for a type of esophageal cancer called squamous cell carcinoma. It aims to find the best approach to shrink the tumor and improve outcomes for patients whose cancer has not spread to distant organs.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06908993RecruitingPhase 3
Tepotinib vs standard care for MET-mutated lung cancer
This trial tests a targeted pill called tepotinib against standard treatments for advanced lung cancer with a specific MET gene change. It is for people whose cancer has progressed after at least one prior therapy.
BesançonAges 18 years+ - NCT06910722Recruiting
Liver transplant for bile duct cancer after treatment
This trial tests if a liver transplant can help people with a certain type of bile duct cancer (intrahepatic cholangiocarcinoma) that cannot be removed by surgery. Before the transplant, you would receive radiation therapy (SIRT) and chemotherapy to shrink the tumor.
Clichy-sous-BoisAges 18–65 - NCT06911333RecruitingPhase 1/Phase 2
A new drug for advanced solid tumors that have stopped responding to treatment
This trial tests a new drug called AD1208 for people with advanced solid tumors that have grown despite previous treatments. The goal is to see if the drug can help where other options no longer work or are not suitable.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT06919029Recruiting
New insulin pump study for children with new type 1 diabetes
This study tests a new insulin pump system (MiniMed 780G) in children aged 7-17 who were recently diagnosed with type 1 diabetes. It aims to see if this pump helps control blood sugar better and improves quality of life compared to standard insulin shots or older pumps.
AthensAges 7–17 - NCT06936735RecruitingPhase 1
HS-20108 for advanced solid tumors (phase 1)
This phase 1 study tests an investigational drug called HS-20108 in people with advanced solid tumors. It aims to find a safe dose and see how well the drug works against cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06940050Recruiting
Gum graft study for lower jaw recessions
This study compares two gum grafting methods (one using a special collagen material plus soft tissue, the other using soft tissue alone) to treat multiple gum recessions on the lower jaw. It may help find a better way to cover exposed roots and improve gum health.
Ghent, Oost-VlaanderenAges 18 years+ - NCT06940388RecruitingPhase 2
Immunotherapy plus standard treatment for rectal cancer
This trial is testing whether adding the immunotherapy drug tislelizumab to standard total neoadjuvant treatment (chemotherapy and radiation before surgery) can improve outcomes for people with locally advanced rectal cancer. The goal is to see if the combination helps shrink the tumor more than standard treatment alone.
MainzAges 18 years+ - NCT06940440RecruitingPhase 1
IFx-Hu2.0 with pembrolizumab for advanced Merkel cell carcinoma
This trial tests a new drug, IFx-Hu2.0, given alongside the immunotherapy pembrolizumab (Keytruda) for people with advanced or spreading Merkel cell carcinoma (MCC). The goal is to see if the combination helps shrink tumors and slow the disease.
Tampa, FloridaAges 18 years+ - NCT06943820RecruitingPhase 1/Phase 2
AK129 combination therapy for advanced solid tumors
This trial tests a new combination of drugs (including AK129) for people with advanced solid tumors, specifically lung cancer, head and neck cancer, or colorectal cancer. It is for those who have already tried a platinum chemo and a PD-1/PD-L1 drug but their cancer got worse.
Shenyang, LiaoningAges 18–75 - NCT06946927RecruitingPhase 1
Study of JMKX001899 with other drugs for advanced KRAS G12C lung cancer
This trial tests a new targeted therapy, JMKX001899, combined with other treatments for advanced non-small cell lung cancer that has a specific KRAS G12C mutation. It aims to see if this combination can help shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18–75
Hear when a new Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced?
- Yes. Clin2 currently lists 3,986 recruiting advanced studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.